According to a retrospective study that was published in "Disease Markers," treating osteoporosis patients with Pamidronate Disodium and Calcium using a mobile terminal platform for the Internet of Things (IoT) can lessen their pain intensity and enhance bone mineral density (BMD). Based on the mobile terminal platform for the IoT, Zuoming Bai et al. set out to investigate impact of Pamidronate Disodium plus Calcium on intensity of pain and BMD values in elderly osteoporosis patients.

Retrospective data analysis was performed on 120 patient records. The patients were segregated into experimental group and control group in accordance with their medical needs and drug preferences. The management of chronic diseases was provided to all patients using mobile IoT terminals, and they were all treated with bisphosphonates and Calcium supplements at a daily dose of 1000 mg. The experimental group received Pamidronate Disodium via intravenous infusion thrice a month whereas the control group received alendronate sodium weekly. The treatment cycle lasted one year. After therapy, the patient's pain scores and BMD levels were compared.

Between the study groups, no clinically meaningful difference was noted in general data. At 6 months and 1 year following treatment, the experimental group's BMD values for the femur neck, the total hip, and lumbar vertebrae L2-4 were considerably greater than those in the control group. Contrasted to the control group, the experimental group's pain ratings at six months and one year following therapy were considerably lower, as shown in Table 1:

On the basis of mobile terminal platform for the IoT, Pamidronate Disodium combined with Calcium therapy was thus beneficial to minimize the intensity of osteoporosis pain.